Evolution, a new five-part series tells the extraordinary story of how life on Earth has changed over more than four billion ...

Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath. The case for Lucid-MS is grounded in more than a decade of rigorous science. Quantum BioPharma's path ...

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...

Why does multiple sclerosis progress quickly in some people, while others remain stable for years? Researchers from the ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the ...

Can exposure to a common pesticide during pregnancy leave a long–term mark on children's brains? A new study examined the ...

A large MS brain study linked specific pathological features with genetic variants, disease severity, and myelin repair, ...

There is currently no cure or treatment for the rare brain disease, but families and researchers hope that could soon change.

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol - - FDA agreed that a single pivotal Phase 3 trial ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental ...

Priority review follows phase 3 placebo-controlled evidence across SatraGO-1/2, presented at ASOPRS 2025, demonstrating improvements in proptosis, inflammation, diplopia, and patient-reported outcomes ...

Millions of people survive heart attacks each year, yet many go on to experience memory lapses, difficulty concentrating, and ...